Personnel Changes in Executive Officer
Filed with TSE · · 1 page · English
Summary by 6ix AI
The Board of Directors resolved these transitions during a meeting.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Veritas In Silico
- TABLE-Veritas In Silico -2025 parent results
- TABLE-Veritas In Silico - 9-MTH parent results
- TABLE-Veritas In Silico -2025 parent forecast
Later from Veritas In Silico
- Joint Patent Application Filed for lncRNA-Targeting Drugs
- Non-consolidated Financial Results for the Six Months Ended June 30, 2026 [Under Japanese GAAP]
- Notice Concerning Achievement of Research Milestone under Joint Drug Discovery with Toray Industries, Inc.
- Notice of Completion of Payment for #5 and #6 to #9 Share Acquisition Rights by Third-Party Allotment
- Syntara and Veritas In Silico sign MoU to Accelerate Joint Discovery Research for mRNA-Targeted Compounds
Follow Veritas In Silico into a list and get an email when it puts out news.
Follow Veritas In Silico